Acetone → Piperazine
Reaction equation
[CH3:1][C:2]1[C:7]([CH2:8][S+:9]([O-:24])[C:10]2[NH:11][C:12]3[CH:13]=[CH:14][C:15]([N:19]4[CH:23]=[CH:22][CH:21]=[CH:20]4)=[CH:16][C:17]=3[N:18]=2)=[N:6][CH:5]=[CH:4][C:3]=1[O:25][CH3:26].C[C:28]([CH3:30])=O.C(Cl)Cl.CC(C)=O>C(Cl)Cl>[CH3:1][C:2]1[C:7]([CH2:8][S+:9]([O-:24])[C:10]2[NH:11][C:12]3[CH:13]=[CH:14][C:15]([N:19]4[CH:20]=[CH:21][CH:22]=[CH:23]4)=[CH:16][C:17]=3[N:18]=2)=[N:6][CH:5]=[CH:4][C:3]=1[O:25][CH3:26].[NH:11]1[CH2:30][CH2:28][NH:18][CH2:17][CH2:12]1Participants
6
Reactant 3
Product 2
Reagents, catalysts & solvents 1
Procedure
A single crystal X-ray diffraction study of racemic ilaprazole, Form F was done using crystals obtained from a acetone/methylene chloride solution. A solution of ilaprazole (˜35.8 mg) and piperazine (˜10.4 mg) was prepared in a solvent mixture of acetone (2.0 mL) and methylene chloride (0.5 mL) at room temperature. Hexanes (5.0 mL) were added to provide a turbid solution. The vial was sealed and the solution was left, undisturbed, at ambient conditions. Racemic ilaprazole, Form F crystals were observed after six days were subsampled from the parent sample.
Workup
- customto provide a turbid solution
- customThe vial was sealed
- waitthe solution was left
Sources & evidence
- ORD record
- ord-2c02c885ccbd4ce9be5e8fabf6dac5e9
- Source dataset
- uspto-grants-2011_08
- Patent number
- US07999110B2
Reaction notes
Loading…